Chongkai Wang1, Ching Ouyang2, May Cho3, Jingran Ji3, Jaideep Sandhu1, Ajay Goel4, Michael Kahn5, Marwan Fakih1. 1. Department of Medical Oncology and Therapeutics Research, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California, USA. 2. Center for Informatics, Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA. 3. Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, California, USA. 4. Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Monrovia, California, USA. 5. Department of Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Abstract
BACKGROUND: The prognostic implication of wild-type APC (APC-WT) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) is not well defined. MATERIALS AND METHODS: APC prognostic value was evaluated retrospectively in two independent cohorts of patient with MSS mCRC with a confirmatory analysis from a public data set from Memorial Sloan Kettering Cancer Center (MSKCC). RESULTS: In comparison with the APC-mutant (APC-MT) population (n = 255), APC-WT patients (n = 86) tended to be younger (59% of age < 40 vs. 26% of age > 50), right-sided (41.7% vs. 27%), BRAFV600E mutated (23.3% vs. 0.8%), and KRAS wild type (65.1% vs. 49.8%). Alternative WNT pathway alterations, RNF43 and CTNNB1, were over-represented in the APC-WT versus APC-MT population (7% vs. 0.4% and 4.7% vs. 0.4%, respectively). APC-WT patients had a worse overall survival (OS) than APC-MT patients (22.6 vs. 45.6 months, p < .0001). Using a multivariate model correcting for primary tumor location, RAS and BRAF status, APC-WT was predictive of poor survival (APC-MT vs. APC-WT, hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.44-0.86, p = .0037). The prognostic implication of APC-WT on OS was confirmed further in a similar multivariate model of 934 stage IV patients from MSKCC public database (APC-MT vs. APC-WT, HR, 0.63, 95% CI, 0.49-0.81, p < .0001). CONCLUSION: APC-WT is associated with poor OS in MSS mCRC regardless of RAS and BRAF status. Compared with APC-MT mCRC tumors, APC-WT tumors were associated with other Wnt activating alterations, including RNF43 and CTNBB1. Our data suggest alternative therapy needs to be investigated in APC-WT patients. IMPLICATIONS FOR PRACTICE: Patients with microsatellite stable metastatic colorectal cancer with wild-type APC had a worse overall survival than patients with mutated APC regardless of RAS/RAF status. APC status should be considered as a stratification factor in prospective trials, and novel therapeutic strategies need to be developed for this subgroup of patients.
BACKGROUND: The prognostic implication of wild-type APC (APC-WT) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) is not well defined. MATERIALS AND METHODS:APC prognostic value was evaluated retrospectively in two independent cohorts of patient with MSS mCRC with a confirmatory analysis from a public data set from Memorial Sloan Kettering Cancer Center (MSKCC). RESULTS: In comparison with the APC-mutant (APC-MT) population (n = 255), APC-WTpatients (n = 86) tended to be younger (59% of age < 40 vs. 26% of age > 50), right-sided (41.7% vs. 27%), BRAFV600E mutated (23.3% vs. 0.8%), and KRAS wild type (65.1% vs. 49.8%). Alternative WNT pathway alterations, RNF43 and CTNNB1, were over-represented in the APC-WT versus APC-MT population (7% vs. 0.4% and 4.7% vs. 0.4%, respectively). APC-WTpatients had a worse overall survival (OS) than APC-MT patients (22.6 vs. 45.6 months, p < .0001). Using a multivariate model correcting for primary tumor location, RAS and BRAF status, APC-WT was predictive of poor survival (APC-MT vs. APC-WT, hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.44-0.86, p = .0037). The prognostic implication of APC-WT on OS was confirmed further in a similar multivariate model of 934 stage IV patients from MSKCC public database (APC-MT vs. APC-WT, HR, 0.63, 95% CI, 0.49-0.81, p < .0001). CONCLUSION:APC-WT is associated with poor OS in MSS mCRC regardless of RAS and BRAF status. Compared with APC-MT mCRC tumors, APC-WT tumors were associated with other Wnt activating alterations, including RNF43 and CTNBB1. Our data suggest alternative therapy needs to be investigated in APC-WTpatients. IMPLICATIONS FOR PRACTICE: Patients with microsatellite stable metastatic colorectal cancer with wild-type APC had a worse overall survival than patients with mutated APC regardless of RAS/RAF status. APC status should be considered as a stratification factor in prospective trials, and novel therapeutic strategies need to be developed for this subgroup of patients.
Authors: Helen H N Yan; Jeffrey C W Lai; Siu Lun Ho; Wai Keung Leung; Wai Lun Law; Janet F Y Lee; Anthony K W Chan; Wai Yin Tsui; Annie S Y Chan; Bernard C H Lee; Sarah S K Yue; Alice H Y Man; Hans Clevers; Siu Tsan Yuen; Suet Yi Leung Journal: Gut Date: 2016-06-21 Impact factor: 23.059
Authors: Christopher H Lieu; Erica A Golemis; Ilya G Serebriiskii; Justin Newberg; Amanda Hemmerich; Caitlin Connelly; Wells A Messersmith; Cathy Eng; S Gail Eckhardt; Garrett Frampton; Matthew Cooke; Joshua E Meyer Journal: Clin Cancer Res Date: 2019-06-26 Impact factor: 12.531
Authors: Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440
Authors: Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz Journal: JCO Precis Oncol Date: 2017-05-16
Authors: Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky Journal: Nat Biotechnol Date: 2013-10-20 Impact factor: 54.908
Authors: Xiaomo Jiang; Huai-Xiang Hao; Joseph D Growney; Steve Woolfenden; Cindy Bottiglio; Nicholas Ng; Bo Lu; Mindy H Hsieh; Linda Bagdasarian; Ronald Meyer; Timothy R Smith; Monika Avello; Olga Charlat; Yang Xie; Jeffery A Porter; Shifeng Pan; Jun Liu; Margaret E McLaughlin; Feng Cong Journal: Proc Natl Acad Sci U S A Date: 2013-07-11 Impact factor: 11.205
Authors: Parvathi A Myer; Jessica K Lee; Russell W Madison; Kith Pradhan; Justin Y Newberg; Carmen R Isasi; Samuel J Klempner; Garrett M Frampton; Jeffery S Ross; Jeffrey M Venstrom; Alexa B Schrock; Sudipto Das; Leonard Augenlicht; Amit Verma; John M Greally; Srilakshmi M Raj; Sanjay Goel; Siraj M Ali Journal: Cancer Discov Date: 2022-05-02 Impact factor: 38.272
Authors: Moom R Roosan; Isa Mambetsariev; Rebecca Pharaon; Jeremy Fricke; Angel R Baroz; Joseph Chao; Chen Chen; Mohd W Nasser; Ramakanth Chirravuri-Venkata; Maneesh Jain; Lynette Smith; Susan E Yost; Karen L Reckamp; Raju Pillai; Leonidas Arvanitis; Michelle Afkhami; Edward W Wang; Vincent Chung; Mihaela Cristea; Marwan Fakih; Marianna Koczywas; Erminia Massarelli; Joanne Mortimer; Yuan Yuan; Surinder K Batra; Sumanta Pal; Ravi Salgia Journal: Cancers (Basel) Date: 2021-06-03 Impact factor: 6.639